These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12270379)

  • 1. Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients.
    Kirchner G; Mueller L; Winkler M; Loss M; Roechte F; Deters M; Christians U; Kaever V; Klempnauer J; Sewing K; Manns M
    Transplant Proc; 2002 Sep; 34(6):2233-4. PubMed ID: 12270379
    [No Abstract]   [Full Text] [Related]  

  • 2. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
    Ettenger RB; Grimm EM
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus (Certican) in combination with neoral in pediatric renal transplant recipients: interim analysis after 3 months.
    Vester U; Kranz B; Wehr S; Boger R; Hoyer PF;
    Transplant Proc; 2002 Sep; 34(6):2209-10. PubMed ID: 12270366
    [No Abstract]   [Full Text] [Related]  

  • 7. Once-a-day administration of everolimus, cyclosporine, and steroid after renal transplantation: a review of the rationale.
    Corbetta G; Ponticelli C
    Transplant Proc; 2010 May; 42(4):1303-7. PubMed ID: 20534286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.
    Budde K; Lehne G; Winkler M; Renders L; Lison A; Fritsche L; Soulillou JP; Fauchald P; Neumayer HH; Dantal J;
    J Clin Pharmacol; 2005 Jul; 45(7):781-91. PubMed ID: 15951468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach.
    Sumethkul V; Tankee P; Chalermsanyakorn P; Jirasiritham S
    Transplant Proc; 2010 Dec; 42(10):4040-2. PubMed ID: 21168621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
    Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
    Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
    Budde K; Neumayer HH; Lehne G; Winkler M; Hauser IA; Lison A; Fritsche L; Soulillou JP; Fauchald P; Dantal J;
    Nephrol Dial Transplant; 2004 Oct; 19(10):2606-14. PubMed ID: 15316094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
    Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
    Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.
    Neumayer HH; Paradis K; Korn A; Jean C; Fritsche L; Budde K; Winkler M; Kliem V; Pichlmayr R; Hauser IA; Burkhardt K; Lison AE; Barndt I; Appel-Dingemanse S
    Br J Clin Pharmacol; 1999 Nov; 48(5):694-703. PubMed ID: 10594471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation.
    Kovarik JM; Kaplan B; Silva HT; Kahan BD; Dantal J; McMahon L; Berthier S; Hsu CH; Rordorf C
    Am J Transplant; 2003 May; 3(5):606-13. PubMed ID: 12752317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with everolimus.
    Augustine JJ; Hricik DE
    Transplant Proc; 2004 Mar; 36(2 Suppl):500S-503S. PubMed ID: 15041396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients.
    Kovarik JM; Dantal J; Civati G; Rizzo G; Rouilly M; Bettoni-Ristic O; Rordorf C
    Am J Transplant; 2003 Dec; 3(12):1576-80. PubMed ID: 14629289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with everolimus (Certican) in young renal transplant recipients.
    Eris J
    Transplantation; 2005 May; 79(9 Suppl):S89-92. PubMed ID: 15880023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.